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Abstract
Background: Helicobacter cinaedi is a rare pathogen in humans, occurring mostly in immuno-
compromised patients, with a high potential for recurrence. We describe a case of a patient with
lymphoma hospitalized for chemotherapy.
Case presentation: At admission, the patient presented with an indolent and non-prurigenic
macular rash around her implantable venous access device. Gram staining of blood cultures
revealed the presence of spiral-shaped gram-negative rods that could not be grown upon
subculture. Helicobacter cinaedi was identified by PCR. No other symptoms or pathology were
observed in a whole body CT scan. The implantable venous access device was removed and empiric
therapy by ceftriaxone and gentamicin for 2 weeks was initiated, followed by peroral clarithromycin
2 × 500 mg/day and later by levofloxacin 2 × 500 mg/day for 7 weeks. Oncologic remission was
achieved 3 months later. However, the patient was re-hospitalized 2 months later for fever,
shivering, reappearance of the macular non-prurigenic rash, diarrhea, cough and asthenia. Blood
cultures grew H. cinaedi. Multiple investigations could not identify the source. Empiric antibiotic
therapy of ceftriaxone and doxycycline was started for 2 weeks with resolution of symptoms,
followed by an oral combination of amoxicillin, metronidazole and doxycycline for 2 months;
doxycycline was continued for another month. Bacteremia has not recurred for a period of 19
months.
Conclusion: Although H. cinaedi is considered to be a low virulent bacteria, its potential to cause
recurrent bacteremia should not be underestimated. H. cinaedi could have an endovascular source
of infection and should be treated for an adequate duration with combined antibiotherapy.
Background
Morphological and genotype studies have shown that dif-
ferent Helicobacter species are involved in animal infec-
tions. Few cause diseases in humans [1].
Helicobacter species have been isolated from the stomach
of various mammals, including dogs, cats, ferrets, pigs,
monkeys and cheetahs, all of which are associated with
various degrees of gastritis in their hosts. Helicobacter spe-
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cies have also been isolated from the intestinal tracts of
humans, animals, and birds [2,3]. The isolation of Helico-
bacter cinaedi from the colon, liver, and mesenteric lymph
nodes of monkeys confirmed its association with hepatitis
and colitis in monkeys [4].
Recent studies suggest that Helicobacter spp. are involved
in cholesterol gallstones in mice and perhaps in humans
[5].
Helicobacter cinaedi, formerly named Campylobacter
cinaedi, is an unusual species in some reported series in
the literature [6]. This pathogen is found predominantly
in severely immuno-compromised patients, such as can-
cer or AIDS patients. It often causes a non-lethal disease
with a high potential for recurrence, requiring long antibi-
otic therapy for several months. H. cinaedi is difficult to
grow on traditional culture media. In the majority of
cases, diagnosis is possible by PCR. The source of infec-
tion is assumed to be intestinal, the hosts are a wide range
of animals, especially hamsters. Asymptomatic carriage
and infection in immuno-competent patients also occur.
In this report we describe a case of recurrent bacteremia
with skin involvement in a patient undergoing chemo-
therapy; this is a rare clinical presentation. The clinical
aspects, therapy pitfalls, a review of the literature and
microbiological difficulties are discussed.
Case presentation
A 53-year-old Caucasian woman without past medical
history was hospitalized in August 2003 in our institution
because of crippling ischialgic pain in her left leg. Investi-
gations revealed a lesion in the left paravertebral and epi-
dural region of the lumbar spine infiltrating the ipsilateral
psoas without metastasis.
Because of exacerbated pain, the appearance of pariesis
(difficulty with dorsal flexion of the foot) in her left leg
and a large number of differential diagnosis, resection of
the paravertebral mass was performed and a portacath
was inserted. Histological examination showed a large B-
cell lymphoma stage IE. Four cycles of chemotherapy were
scheduled with cyclophosphamide, doxorubicin, vincris-
tine and prednisolone in association with methotrexate
and monoclonal anti-CD20 antibody. The patient toler-
ated the first cycle well; agranulocytosis appeared for 4
days (neutrophil count 180 g/l). The leg paresis subsided
completely.
At admission for the second cycle of chemotherapy in Sep-
tember 2003, a transient pink macular rash appeared
around the skin orifice of the implantable venous access
device. No other clinical symptoms were present. Labora-
tory examinations revealed a C-reactive protein (CRP) of
29 mg/l and a left shift in the leukocyte count of 8%. This
slight inflammation could not be explained by the lym-
phoma alone since previous CRP values were within the
normal range. Blood cultures were performed. The rash
disappeared spontaneously and the patient became
asymptomatic.
Blood cultures were performed using an automated blood
culture system (Bactec 9240 Becton Dickinson Diagnostic
Instrument Systems, Sparks, MD, USA).
A positive aerobic blood culture vial was indicated after 3
days of incubation. Anaerobic cultures were negative.
Gram staining was negative, but Acridine Orange staining
revealed a spiral bacterium (figure 1A). Subculture of the
positive vials was performed on blood agar plates and
chocolate media incubated in a micro-aerobic (5% O2, 5
to 10% H2) and an anaerobic atmosphere at 35°C, gener-
ated with incubation jars in atmosphere generators (GEN-
box, bioMèrieux SA, Lyon, France). All subcultures
remained negative after 5 days, therefore PCR and subse-
quent sequencing of the 16S rRNA gene was performed on
the positive broth. The definitive identification of H.
cinaedi was achieved by sequencing the product of PCR
based on the data of 16S rRNA comparing the nucleotide
sequence homology with the GenBank database, where a
99.6% homology was found with H. cinaedi (accession
number AF 426158). We used the following primer
sequences: Primer b 162 5' GAG AGT TTG ATC XTG GCT
CAG 3' (Microsynth GmBH) (-20°C). Primer BR-16SR 5'
CGC TCG TTG CGG GAC TTA A 3'(Microsynth GmBH) (-
20°C).
Additional blood cultures indicated the presence of the
same micro-organism and empiric antibiotic therapy with
intravenous ceftriaxone 1 × 2 g/day and a catheter lock
Acridine Orange staining: spiral bacterium and gram-negative  rods Figure 1
Figure 1A: Acridine Orange staining: spiral bacterium.  
Figure 1B: Gram-negative rods.
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technique with gentamicin 5 mg/day was administered
for 2 weeks.
Despite significant regression of all inflammatory param-
eters, control blood cultures remained positive for the
same organism. The implantable venous access device was
removed since an infection of the central vascular access
was suspected in absence of another clinical symptoms.
Cultures of the implantable venous access device
remained negative but bacteremia persisted for another 4
days suggesting another source. However, no other source
was found. A whole body computer tomography (CT)
scan did not reveal any suspect lesions. Magnetic reso-
nance imaging (MRI), performed due to a headache,
revealed an aneurysm, 8 mm in diameter, in the left pos-
terior communicating artery (P2-P3). Coiling was per-
formed with the placement of a detachable platinum coil,
believed to be less susceptible to infections than other
metals. Discussion arose whether this aneurysm could be
of mycotic or congenital origin. No biopsy for histological
analysis could be obtained and no previous cerebral
images existed. The presence of an aneurysm in a region
known for congenital aneurisms led us to diagnose a con-
genital origin.
After the intravenous treatment, an oral regimen of clari-
thromycin 2 × 500 mg/day followed by levofloxacin 2 ×
500 mg/day was administered for 7 weeks.
The patient underwent three cycles of chemotherapy and
40 Gy of radiotherapy. In January 2004, the patient was
considered to be in complete remission with good clinical
evolution and she returned to work; the only complaint
was symmetric arthralgia in the elbows and knees of
unknown origin.
However, in March 2004, the patient was re-hospitalized
due to a fever (39°C), shivering, watery diarrhea, vomit-
ing, fatigue, unproductive cough, and a diffuse, red, mac-
ular, patchy cutaneous rash all over the body with the
exception of mucosal surfaces. The initial suspicion of a
viral infection was revised 5 days later when a spiral gram-
negative rod was detected in the blood cultures. The CD4
count revealed 290 cells/mm3 attributed to her chemo-
therapeutic immuno-compromised state. During this sec-
ond episode of bacteremia, positive blood cultures again
revealed a spiral, helical gram-negative rod (figure 1B).
This time, subcultures were successful; colonies grew on
blood agar incubated in a micro-aerobic (5% O2) atmos-
phere. Again, the identification of H. cinaedi was obtained
by PCR and sequencing of the 16S rRNA gene.
Minimal inhibitory concentrations (MIC) of potentially
active antimicrobials were determined on blood agar
incubated micro-aerobically at 35°C with the E-test
method for clarithromycin, ciprofloxacin, erythromycin,
trimethoprim-sulfamethoxazole, metronidazole and
amoxicillin. Interpretation of susceptibility in vitro was
based on the NCCLS guidelines for H. pylori for clarithro-
mycin, and on published reports for metronidazole and
amoxicillin [7,8]. For the other antibiotics, the interpreta-
tion was based on the NCCLS guidelines for gram-nega-
tive bacilli. The strain was susceptible to amoxicillin (MIC
= 0.75 mg/l) and to metronidazole (MIC = 0.25 mg/l),
intermediate to clarithromycin (MIC = 3 mg/l) and resist-
ant to the other antibiotics tested (erythromycin, trimeth-
oprim-sulfamethoxazole and ciprofloxacin).
After 2 weeks of successful intravenous ceftriaxone 1 × 2 g/
day and peroral doxycycline 2 × 100 mg/day therapy, this
regimen was changed to a peroral outpatient treatment.
The patient received doxycycline 2 × 100 mg/day, metro-
nidazole 3 × 500 mg/day and amoxicillin 3 × 750 mg/day
for 2 months followed by doxycycline alone for a third
month, following an empiric eradication therapy for Heli-
cobacter pylori. The patient had a good laboratory and clin-
ical response.
Multiple examinations were repeated in order to detect
the possible source of the recurrent infections, such as
whole body CT scan, transesophageal echocardiography,
bacterial stool cultures, colonoscopy with multiple biop-
sies, bone scintigraphy and cerebral angiographic MRI.
No pathology, no recurrent neoplastic disease or cerebral
aneurysms were found. An unspecific inflammation was
seen in the colonoscopy without histological evidence of
bacterial infection. This observation was attributed to the
patient's post-irradiation status. Further investigations
were abandoned due to the favorable progress under anti-
biotic therapy. The source of the recurrent infection could
not be identified but was presumed to be either of
endovascular or intestinal origin.
In November 2005, 19 months after the recurrence, the
patient is in complete remission and in good clinical con-
dition.
Discussion
Like other non-pylori Helicobacters, H. cinaedi is an unu-
sual pathogen in humans and difficult to culture with the
normal routine procedures. Since the first cases of procto-
colitis in male AIDS patients were described in 1985 [9],
several other cases have been reported in the literature.
Asymptomatic carriage certainly occurs. The micro-organ-
ism, considered to be enterohepatic, seems to have a low
degree of virulence. It is regarded as an opportunist.
Recently, Taylor et al. [10] reported for the first time an
important putative virulence factor in H. cinaedi con-
firmed by the production of cytolethal distending toxin,
which causes distention in cells and arrest in the G2/MBMC Infectious Diseases 2006, 6:86 http://www.biomedcentral.com/1471-2334/6/86
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phase of cell division. Also motility by means of flagella is
generally regarded as a virulence determinant in Helico-
bacter and Campylobacter species. H. cinaedi shares the pro-
duction of cytolethal distending toxin with other enteric
pathogenic species. H. cinaedi may cause symptomatic
diseases in immuno-compromised patients, such as those
with HIV, cancer or after transplantation [9,11-18].
Rare cases of disease in immuno-competent patients have
been reported [19,20]: a patient with bacteremia and
arthritis [19] or erysipelas [20], several patients with recur-
rent fever and rash [11], and in neonates [21]. Interest-
ingly, all immuno-competent patients and neonates with
H. cinaedi disease had been in contact with animals [19].
Other cases of bacteremia in immuno-compromised
patients after renal failure [22] and X-linked agammaglob-
ulinemia [23] have also been published in the literature.
The route of infection is rarely known, and presumed to
be oral. As a reservoir, H. cinaedi has been identified in
many animals, for example, rats, hamsters, dogs, cats,
foxes, poultry, wild birds, and monkeys. Hamsters, in par-
ticular, are known to be a common natural reservoir [24].
The role of the micro-organism in these animal hosts is
unknown. Interestingly, our patient's daughter, living in
the same household, fed her pet snake with rats. The
snake died several months before the mother's illness.
Perhaps both mother and daughter have been asympto-
matically infected for a long time by the rats the snake was
fed with. Rats are known to be carriers of H. cinaedi [25].
Symptoms could have emerged in the mother after
immuno-suppressive chemotherapy. We assume that the
patient would not have experienced the H. cinaedi infec-
tion without the associated lymphoma and the chemo-
therapy. Cultures from the daughter were not possible to
perform.
H. cinaedi infections may present various clinical manifes-
tations, ranging from proctocolitis [9], gastroenteritis
[26], meningitis in neonates [21], localized pain [27],
rash, or bacteremia [13]. The more immuno-compro-
mised the patients, the more severe are the symptoms.
Nevertheless, Kiehlbauch et al. [11] reported that two
symptoms are predominant, namely fever and rash [11].
Our case presented both symptoms, whereas the addi-
tional symptoms of diarrhea and arthralgia are less fre-
quently reported [11]. In our case, H. cinaedi could not be
isolated from the colonoscopic biopsies and stool cul-
tures. Other infectious agents could not be identified in
the stool cultures.
The origin of the first bacteremia in our case remains
unknown but we have assumed it to be the gastrointesti-
nal tract since the mucosal cells have been damaged by
combined chemo- and radiotherapy.
Our investigations revealed a cerebral aneurysm of the
posterior communicating artery. Its localization and its
single status indicate a possible congenital origin. No new
aneurysms or change in size were observed during the sec-
ond episode of bacteremia. A whole body angiography of
the large arteries did not reveal an endovascular origin.
H. cinaedi is a fastidious organism, rendering microbio-
logical diagnosis difficult. It rarely grows on traditional
culture media [25]. At best, growth may be obtained on
rich, non-selective media (blood or chocolate agar) incu-
bated in a micro-aerobic (5% O2) atmosphere at 35°C
[11]. The diagnosis is mainly established by gene amplifi-
cation techniques such as PCR and subsequent sequenc-
ing [28]. With these techniques, however, antimicrobial
susceptibility in vitro cannot be determined.
No clear guidelines are available in the literature concern-
ing the choice or duration of antibiotic therapy. Many
antibiotic agents, alone or in combination, have been suc-
cessfully used, such as penicillin, ampicillin, cefazolin,
erythromycin, ciprofloxacin, aminoglycosides, tetracy-
clines and rifampicin [11,19,21,29]. A large review of 23
cases of bacteremia reported that penicillins, tetracycline,
and aminogylcosides are more effective than cepha-
losporins, erythromycin, or ciprofloxacin. Erythromycin
resistant H. cinaedi has also been identified [30]. Quinolo-
nes alone may not completely eradicate H. cinaedi, which
explains the frequent reports of recurrent disease after qui-
nolone monotherapy [11].
The reported duration of antibiotherapy for H. cinaedi
bacteremia ranges from 10 days to 12 weeks [19,29]. Due
to the frequent recurrences, prolonged antibiotic treat-
ment is necessary [11-13]. In our case, a 2-week course of
combined antibiotherapy with ceftriaxone and gen-
tamicin, followed by 5 weeks of peroral clarithromycin
and levofloxacin was not able to eradicate the micro-
organism despite its susceptibility in vitro. Other possible
reasons that could explain the recurrent illness were
excluded, such as malabsorption, suspected malcompli-
ance or macroscopic intestinal lesions. We therefore chose
to treat the second recurrent episode for a sufficiently long
3-month period; so far it has been successful.
Conclusion
In conclusion, we report that recurrent bacteremia due to
H. cinaedi without any anatomic lesion may occur; the
micro-organism may re-emerge and prolonged antibiotic
treatment is necessary. Optimal antimicrobial treatment
and its duration remain to be established.
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